(USNA) USANA Health Sciences - Ratings and Ratios

USANA Health Sciences Inc. (NYSE:USNA) is a global leader in the development, manufacturing, and distribution of high-quality, science-based nutritional supplements, personal care, and skincare products. With a strong presence in the Asia Pacific, Americas, and Europe, the company caters to diverse markets with a wide range of products designed to promote overall health and well-being. USANAs nutritional product line includes essentials such as CellSentials, which provide foundational vitamin and mineral supplements for various age groups, optimizers targeting specific health needs like cardiovascular and digestive health, and meal replacement options such as shakes and snack bars. The company also offers Celavive, a skincare regimen tailored for different skin types and ethnicities, and specialized products for prenatal, infant, and young child nutrition. USANA supports its network of associates with business-building tools and online resources, enhancing their marketing efforts. Products are available through both retail stores and online platforms. USANA has established research collaborations with prestigious institutions like Beijing University of Chinese Medicine and the National Sports Training Bureau, underscoring its commitment to innovation and quality. Founded in 1992, USANA is headquartered in Salt Lake City, Utah, and is recognized for its dedication to R&D and customer-centric approach. Web URL: https://www.usana.com

3-Month Forecast: Based on the provided data, USANAs stock is expected to experience a period of consolidation. The SMA 20 and SMA 50 indicate a downward trend, with the stock trading below these levels, suggesting potential near-term weakness. However, the forward P/E ratio of 11.00, slightly below the current P/E of 11.23, may signal modest expectations for future earnings growth. The price-to-sales ratio of 0.70 indicates a reasonable valuation relative to its revenue. The Average True Range (ATR) of 1.28 suggests moderate volatility, which could lead to price fluctuations within a narrow range. Support levels may form near the SMA 200 of 39.38, though the stock is currently trading below this level, indicating bearish sentiment. Investors may await further catalysts, such as earnings reports or new product launches, before making significant moves. Overall, the stock is likely to remain under pressure in the short term but could stabilize as it approaches key support levels.